

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/820,749	03/30/2001	Masayuki Motonari	205429US0	3881
22850	7590 05/21/2004		EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			WOOD, ELIZABETH D	
	940 DUKE STREET LEXANDRIA, VA 22314		ART UNIT	PAPER NUMBER
			1755	
			DATE MAILED: 05/21/2004	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/820,749	MOTONARI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Elizabeth D. Wood	1755			
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the o	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPI THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reg. If NO period for reply is specified above, the maximum statutory period. Failure to reply within the set or extended period for reply will, by statur. Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	. 136(a). In no event, however, may a reply be tile by within the statutory minimum of thirty (30) day I will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	mely filed ys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 04 l	November 2002.				
	<u> </u>				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1-54 is/are pending in the application 4a) Of the above claim(s) is/are withdress 5) Claim(s) is/are allowed. 6) Claim(s) 1-54 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/ Application Papers	awn from consideration.  for election requirement.				
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre	• , ,	• •			
11) The oath or declaration is objected to by the E	,	* * * * * * * * * * * * * * * * * * * *			
Priority under 35 U.S.C. § 119					
a) All b) Some * c) None of:  1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the pri application from the International Bure. * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat ority documents have been receiv au (PCT Rule 17.2(a)).	tion No red in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 13.	4) Interview Summan Paper No(s)/Mail D 5) Notice of Informal 6) Other:				

Art Unit: 1755

## Information Disclosure Statement

The application file record indicates the filing of Information Disclosure Statements on July 2, 2001. July 9, 2001 and October 10, 2001, but these are not present with the application file. If applicants will submit copies of the PTOL-1449 documents and the foreign references, these papers will be considered with the next office action.

#### Election/Restriction

Applicants' election with traverse of the species "a heterocyclic compound with a heteropentacycle, with no benzene forming the skeleton, and with a functional group", specifically 7-hydroxy-5-alkyl-1,3,4-triazaindolizine in Paper No. 9 is acknowledged. The traversal is on the grounds that the office has not provided any reasons or examples to support a conclusion that the species are patentably distinct. This is not convincing. Clearly, a reference teaching, for example, a thiourea component would not be used to reject a claim to 7-hydroxy-5-alkyl-1,3,4-triazaindolizine because the substances are so structurally different, as would be recognized and appreciated by one skilled in the art.

Regarding the "burden" on the examiner, it is pointed out that the potential species run from page 3 through page 13 of this application. The examiner submits that searching and examining this large number of species is clearly evidence of burden.

The election of species requirement is still deemed proper and is hereby made FINAL.

Art Unit: 1755

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim12 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claim recites "any one of Claim 11" which should be corrected.

### Claim Rejections - 35 USC § 102, 103

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

Art Unit: 1755

1. Determining the scope and contents of the prior art.

- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicants are advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-54 are rejected under 35 U.S.C. 102(e) or 103(a) as being obvious over U.S. Patent No. 6,579,153 to Uchikura et al.

The applied reference has a common inventor with the instant application.

Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and

Art Unit: 1755

reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). For applications filed on or after November 29, 1999, this rejection might also be overcome by showing that the subject matter of the reference and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person. See MPEP § 706.02(I)(1) and § 706.02(I)(2).

Uchikura et al. disclose aqueous dispersions for CMP that comprise an abrasive and a heterocyclic compound that can be 7-hydroxy-5-methyl-1,3,4-triazaindolizine.

This disclosure is considered to anticipate the claimed composition.

Alternately, the reference can be considered to differ slightly in scope from the instant claims because it suggests that the composition can also contain an organic acid. However, the instantly claimed invention would have been obvious because additional components are not excluded by the instant claims. See particularly column 3, column 8 and column 12.

Applicants cannot rely upon the foreign priority papers to overcome this rejection because a translation of said papers has not been made of record in accordance with 37 CFR 1.55. See MPEP § 201.15.

Claims 1-54 are rejected under 35 U.S.C. 103(a) as being obvious over U.S. Patent No. 6,582,761 to Nishimoto et al.

**Art Unit: 1755** 

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). For applications filed on or after November 29, 1999, this rejection might also be overcome by showing that the subject matter of the reference and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person. See MPEP § 706.02(I)(1) and § 706.02(I)(2).

Nishimoto et al. disclose a CMP comprising an aqueous dispersion containing a composited particle which reads on the instantly claimed abrasive material. The material also contains a complexing agent comprising heterocyclic compounds such as the herein elected 7-hydroxy-5-methyl-1,3,4-triazaindolidine. See particularly column 18.

Art Unit: 1755

Applicants cannot rely upon the foreign priority papers to overcome this rejection because a translation of said papers has not been made of record in accordance with 37 CFR 1.55. See MPEP § 201.15.

### **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-54 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 3 and 11 of copending Application No. 10/200,504. Although the conflicting claims are not identical, they are not patentably distinct from each other because they differ from one another only in the scope of coverage being sought. The copending claims require and aqueous dispersion with polymer particles and a complexing agent. The particles read on the instantly claimed abrasive and the complexing agent as defined by the specification can be a heterocyclic compound such as that claimed herein. See paragraph [0037] and examples 11 and 14 for definition of the complexing agent.

Art Unit: 1755

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1-54 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 6,447,695. Although the conflicting claims are not identical, they are not patentably distinct from each other because they differ from one another only in the scope of coverage being sought. The patented claims recite an aqueous dispersion comprising a "polishing agent" that reads on the instantly claimed abrasive and a "polishing rate adjustor" that can be the elected heterocyclic compound 7-hydroxy-5-methyl-1,3,4-triazaindolizine. Accordingly, the two sets of claims are drawn to substantially the same inventive concept.

Claims 1-54 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 7-32 of U.S. Patent No. 6,579,153. Although the conflicting claims are not identical, they are not patentably distinct from each other because although the claims recite a method for forming an embedded wire rather than the instantly claimed aqueous dispersion, they require use of the same composition being claimed by applicants and the composition itself is therefore set forth in the patented claims.

#### Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Art Unit: 1755

Applicants are advised that any evidence to be provided under 37 CFR 1.131 or 1.132 and any amendments to the claims and specification should be submitted prior to final rejection to be considered timely. It is anticipated that the next office action will be a final rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth D. Wood whose telephone number is 571-272-1377. The examiner can normally be reached on M-F, 5:30-2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Bell can be reached on 571-272-1364. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Eliźabeth D. Wood Primary Examiner Art Unit 1755